Henderson Jane
Henderson Jane, DIR, reported a transaction classified as grant at Lycia Therapeutics, Inc. involving 20000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 20000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 22, 2026
- Filing date
- Oct 26, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
LYCA price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001422304-26-000005 Stock Option (Right to Buy)
- Transaction date
- Oct 22, 2026 Filed Oct 26, 2026, 11:05 PM · 4d delay
- Shares
- 20,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 20,000 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-10 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transa…
- F2
The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on August 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each ve…
- F3
The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
0 other transactions
0 recent txs